Drugs.com Clinical Trial ResultsOriginal article
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
RegulatoryapprovedOpaganibPositive
AI Analysis
Summary
RedHill Biopharma announced that opaganib received FDA Rare Pediatric Disease Designation for neuroblastoma, in addition to its existing orphan drug designation. This regulatory recognition supports the development pathway for the pediatric indication.
Outcome Details
FDA granted Rare Pediatric Disease Designation for neuroblastoma
Importance:5/10
Sentiment:
0.70
regulatorypediatricorphan drugrare diseaseneuroblastoma
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on June 9, 2026 8:07 PM